SHANGHAI HAOYUAN CHEMEXPRESS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.32 CNY | +1.06% |
|
+6.61% | -32.16% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 2.45B 339M | Sales 2025 * | 3.16B 437M | Capitalization | 5.31B 735M |
|---|---|---|---|---|---|
| Net income 2024 * | 157M 21.73M | Net income 2025 * | 226M 31.28M | EV / Sales 2024 * | 2.17 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
29.8
x | P/E ratio 2025 * |
20.7
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 41.43% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.06% | ||
| 1 week | +6.61% | ||
| Current month | +6.61% | ||
| 1 month | +9.89% | ||
| 3 months | +2.70% | ||
| 6 months | -47.28% | ||
| Current year | -32.16% |
1 week
33.50
35.85
1 month
28.4335.85
Current year
26.0051.99
1 year
26.0079.64
3 years
26.00216.84
5 years
26.00216.84
10 years
26.00216.84
| Managers | Title | Age | Since |
|---|---|---|---|
Qiang Gao
FOU | Founder | 51 | 06-09-29 |
Bao Fu Zheng
CEO | Chief Executive Officer | 45 | 06-09-29 |
Yu Chen Zhang
CHM | Chairman | 56 | 20-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bin Yuan
BRD | Director/Board Member | 43 | 19-12-19 |
Yun Chen
BRD | Director/Board Member | 38 | 15-12-22 |
Bao Fu Zheng
CEO | Chief Executive Officer | 45 | 06-09-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 35.32 | +1.06% | 2,505,838 |
| 24-05-07 | 34.95 | +0.89% | 1,671,662 |
| 24-05-06 | 34.64 | +4.56% | 1,852,691 |
| 24-04-30 | 33.13 | -0.69% | 1,385,106 |
End-of-day quote Shanghai S.E., May 07, 2024
More quotes
Shanghai Haoyuan Chemexpress Co Ltd is a China-based company mainly engaged in the research and development, production and sales of small molecule drugs. The Company's main products include molecular building blocks and tool compounds. The Company's products also include active pharmaceutical ingredients (APIs) and intermediates. The Company also provides related services such as contract research organization (CRO) service. The Company's molecular building blocks and tool compounds are applied in all stages of the drug discovery process. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
35.32
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.16% | 735M | |
| -3.35% | 88.91B | |
| +4.08% | 41.25B | |
| -15.09% | 31.99B | |
| +51.27% | 24.73B | |
| -15.13% | 15.54B | |
| -8.63% | 12.05B | |
| -40.39% | 12.07B | |
| +6.22% | 8.84B | |
| -5.15% | 8.3B |
- Stock Market
- Equities
- 688131 Stock